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PEMBANGUNAN DAN PENILAIAN FORMULASI GEL BIOADHESIF, 
TERMOSENSITIF, PEMBENTUKAN IN SITU GEL METRONIDAZOL 





    Rawatan bagi penyakit periodontal adalah bertujuan untuk menyingkirkan 
patogen yang menyebabkan penyakit dan mengurangkan keradangan tisu. Rawatan 
dengan‎ “scaling and root planning” bukan pembedahan boleh meninggalkan 
mikroorganisma yang membawa kepada penjajahan semula. Administrasi oral ubat 
anti-mikrob dan anti-keradangan, walaupun pada dos terapeutik kepada pesakit 
boleh membawa kesan sampingan. Administrasi local ubat mengatasi kelemahan 
administrasi laluan lain. Objektif kajian ini adalah untuk menghasilkan formulasi 
gelkebolehpicagarian, bioadhesif, pelepasan tertahan, termosensitif, pembentukan in 
situ metronidazol dan kalium diklofenak untuk merawat penyakit periodontal, yang 
boleh diberikan secara langsung ke tapak tindakan. Kaedah HPLC-UV yang mudah 
yang boleh menentukan kepekatan metronidazole dan kalium diklofenak serentak 
telah dibangunkan dan disahkan. Kaedah tersebut adalah spesifik, tepat dan jitu. 
Puncak kedua-dua drug boleh dipisahkan dengan resolusi yang baik. Masa analisis 
sampel kurang daripada 12 minit. Kaedah ini telah digunakan dalam esei drug, 
kajian pelepasan drug in vitro, kajian penembusan drug in vitro dan kajian 
kestabilan formulasi gel. Poloxamer 407 dan 188 digunakan untuk menghasilkan 
formulasi gel in situ. Poloxamer 30% (poloxamer 407 dan 188 dalam nisbah 2:1) 
menunjukkan suhu penggelan yang mendekati suhu fisiologi rongga mulut. Gam 
  
xxv 
xanthan dan Carbopol 934 ditambahkan dalam formulasi gel untuk memberikan sifat 
bioadhesif dan mengawal pelepasan drug. Peningkatan kandungan gam xanthan atau 
Carbopol 934 mengurangkan pelepasan metronidazole dan kalium diklofenak. Gam 
xanthan memberi kesan yang lebih ketara dalam pengurangan pelepasan kedua-dua 
drug berbanding dengan Carbopol 934. Formulasi gel didedah terhadap analisis 
profil tekstur, pengukuran bioadhesif, kebolehpicagarian dan penilaian reologi. 
Formulasi gel yang mengandungi gam xanthan memberi sifat Newtonian apabila 
disimpan pada suhu 8 °C dan boleh mengalir melalui picagari pada suhu fisiologi 
(37 °C). Formulasi gel memaparkan sifat pseudoplastik dengan histeresis. Lebih 
kurang 20% metronidazol dan kurang daripada 3% kalium diklofenak menembusi 
mukosa pada 120 jam (hari-5). Formulasi gel yang optimum (Gel 3) menunjukkan 
struktur yang sangat poros dengan rongga apabila diperiksa dengan mikroskop 
elektron pengimbasan. Drug tersebar formulasi  tapak gel apabila diperiksa dengan 
mikroskop elektron transmisi. Gel 3 merencat pertumbuhan bakteria aerobik (S. 
aureus dan E.coli) dan anaerobik (P. gingivalis dan St mutans). Di samping itu, Gel 
3 dapat mengurangkan keradangan tapak kaki yang diakibatkan oleh karrageenan, 
membuktikan keberkesanannya dalam mengurangkan keradangan. Kesan 
penyembuhan Gel 3 disiasat selepas pembekalan 7 hari pada penyakit “ligature-
induced periodontal” pada tikus. Rawatan dengan Gel 3 yang mengandungi  kedua-
dua drug mempercepatkan penyembuhan tisu-tisu yang terjangkit dan meradang. 
Secara kesimpulan, formulasi kebolehpicgarian, bioadhesif, pelepasan terkawal, 
termosensitif pembentukan gel in situ metronidazol dan kalium diklofenak, yang 





DEVELOPMENT AND EVALUATION OF BIOADHESIVE, 
THERMOSENSITIVE, IN SITU GELLING FORMULATION OF 
METRONIDAZOLE AND DICLOFENAC POTASSIUM FOR TREATMENT 
OF PERIODONTAL DISEASE 
 
ABSTRACT 
   The target in treatment of periodontal disease is to eliminate the pathogens 
responsible for infection and decrease the tissue inflammation. Treatment using non-
surgical scaling and root planning could leave behind microorganisms leading to re-
colonization. Administration of anti-microbial and anti-inflammatory drugs orally, 
even at therapeutic doses in patients leads to some side effects. Local administration 
of drugs obviates the drawbacks of other routes of administration. The study was 
aimed to develop a syringeable, bioadhesive, sustained release, thermosensitive in 
situ gelling formulation of metronidazole and diclofenac potassium for the treatment 
of periodontal disease, which was delivered directly to the site of action. A simple 
HPLC-UV method that could simultaneously determine metronidazole and 
diclofenac potassium concentrations was developed and validated. The method was 
specific, precise and accurate. The two drug peaks were well resolved with good 
resolution. The sample run time was less than 12 min. The method was applied in 
drug assay, in vitro drug release study, in vitro drug permeation study and stability 
study of the gel formulations. Poloxamers 407 and 188 were used to prepare the in 
situ gelling formulations. Poloxamer of 30%w/w (poloxamer 407 and 188 at ratio of 
2:1) showed gelation temperature close to the physiological temperature of the oral 
cavity. Xanthan gum and Carbopol 934 were incorporated to provide bioadhesive 
properties and sustain the drug release. Increase in xanthan gum or Carbopol 934 
  
xxvii 
content decreased both metronidazole and diclofenac potassium release. Xanthan 
gum exhibited more retardation than Carbopol 934 on release of both drugs. The gel 
formulations were subjected to texture profile analysis, bioadhesive measurement, 
syringeability and rheological evaluation. Xanthan gum loaded gel formulations 
showed Newtonian behavior when stored at 8 °C and flowed through syringe at 
physiological temperature (37 °C). The gel formulation exhibited pseudoplastic 
behavior with hysteresis. Approximately 20% of metronidazole and less than 3% of 
diclofenac potassium permeated through the mucosa at 120 hr (day-5). The 
optimized gel formulation (Gel 3) showed highly porous structure with voids when 
examined under scanning electron microscope. Drug distributed in the gel base 
when observed under transmission electron microscope. Gel 3 inhibited the growth 
of both aerobic (S. aureus and E.coli) and anaerobic (P. gingivalis and St. mutans) 
bacteria. In addition, Gel 3 reduced the carrageenan induced paw inflammation, 
indicating its effectiveness in reducing inflammation. The healing effect of Gel 3 
was investigated after application for 7 days on ligature-induced periodontal disease 
in rats. The treatment with Gel 3 containing both drugs accelerated the healing of the 
infected and inflamed tissues. In conclusion, a syringeable, bioadhesive, sustained 
release, thermosensitive in situ gelling formulation of metronidazole and diclofenac 
potassium which could be delivered once a week for the treatment of periodontal 











1.1   Periodontal disease  
The term periodontal disease or gum disease can be defined as a local infection and 
/or inflammation of the gingival and supporting ligament to the teeth. Periodontal 
disease is one of the huge public health problems. Initially, the inflammation is only 
localized to the gum, but with time the inflammation protrudes deeper and the 
pockets are formed where bacteria reside. In severe cases, loss of teeth and bone 
resorption can occur (Jain et al., 2008; Joshi et al., 2016).  
 
1.2   Prevalence 
World Health Organization (2012) considered periodontal disease as one of the two 
significant global burdens of oral disease with dental caries. WHO claimed that 10 –
15% of the population worldwide, independent of ethnicity, suffered from 
periodontal disease. Across age groups, caries and periodontal diseases are among 
the most prevalent diseases in mankind and if untreated, could lead to tooth loss, 
poor nutrition, loss of self-esteem, social difficulties and diminished quality of life 
(Tonetti et al., 2017). Severe periodontitis is now recognized as being the sixth most 
prevalent disease  for human (Steele‎ &‎ O’Sullivan,‎ 2011). The common oral 
diseases among children are gingivitis and dental caries, which affect 60-90% of 
school children globally (Jürgensen & Petersen, 2013). Khan et al. (2015) studied 
the prevalence of chronic periodontitis in obese Malaysian population. The 




1.3   Treatment of periodontal diseases 
Microbial colonization on the teeth is a major source of pathogens responsible for 
periodontal disease, gingivitis, post extraction infections and endodontitis. It 
involves Gram-positive (such as Streptococcus viridians, Peptostreptococcus and 
Staphylococcus species) and Gram negative (such as E. coli, Porphyromonas. 
gingivalis, Tannerella, forsythensis, Treponema denticola, Actinobacillus 
actinomycetemcomitans and Fusobacterium nucleatum) bacteria (Souto et al., 2006; 
Cawson & Odell, 2008). The presence of bacteria can release toxins that lead to a 
cascade of inflammatory events. The resulting inflammation affects the periodontal 
ligament, causing breakdown of tissues and bones supporting the teeth. This leads to 
formation of space which acts as a reservoir for growth and multiplication of 
microorganisms. 
The main target of periodontal disease treatment is to eliminate the pathogens 
responsible for infection and decrease tissue inflammation. Antimicrobial agents and 
non-steroidal anti-inflammatory drugs have been used to treat periodontal disease. 
When there is no inflammation, antimicrobial agents along with mechanical method 
is used (Tariq et al., 2012).  
 
1.4   Problem statement 
The current treatment of periodontal disease can be broadly categorized into surgical 
and non-surgical methods (Heitz‐ Mayfield et al., 2002). The non-surgical method 
involves scaling and root planning (SRP) or curettage with anesthesia (Heitz 
Mayfield et al., 2002). The method leads to a reduction in microbial load and 
bleeding time upon probing. However, this process could leave behind 




In addition to SRP method, the non-surgical method involves the use of 
antimicrobial agent and anti-inflammatory drug, which are administered orally or 
applied locally to the site of action. The oral and local administrations of 
antimicrobial agents are illustrated in Figure 1.1.  
 
The non-surgical method using local administration has the advantages of avoidance 
of hepatic and intestinal metabolism, time consuming surgical method, and drug 
delivery direct to the diseased site. Various local drug delivery systems have been 
developed which can be broadly classified into fibers, films, gels, rods, discs, chips, 
spheres, nanoparticles and vesicles. 
 
 
Figure 1.1. Oral and local administration of antimicrobial agents (adapted from 






Some of the local drug delivery systems need to be removed (except formulations 
containing biodegradable polymers like  poloxamer, xanthan gum etc.). Hitherto, the 
commercially available local drug delivery systems for the treatment of periodontitis 
contain only antimicrobial agent.  
 
The delivery system in this research was a bioadhesive, in situ gelling formulations 
containing a combination of two drugs an antimicrobial and a non-steroidal anti-
inflammatory drug, delivered directly to the site of action. The drug was retained at 
the site of application and the drug was released over a period of time eliminating 
the need for frequent reapplication. 
 
1.5   Scope of study 
The aim of the present study is to design and evaluate bioadhesive, thermosensitive, 
in situ gelling formulations of metronidazole and diclofenac potassium, for local 
delivery at the site of application for the treatment of periodontal disease. The gel 
should be retained in the periodontal pocket and the drug release can be sustained 
over a period of time.  
The experiments have been planned out in various stages as stated below:  
1. To develop HPLC-UV method for simultaneous determination of 
metronidazole and diclofenac potassium. 
2. To develop and characterize bioadhesive, thermosensitive, in situ gelling 
formulations of metronidazole and diclofenac potassium. 
3. To evaluate the antibacterial and anti-inflammatory effect of the optimized gel 
formulation of metronidazole and diclofenac potassium. 
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4. To investigate the efficacy of gelling formulation incorporated with 
metronidazole, diclofenac potassium or both metronidazole and diclofenac 

























2.1  Classification of periodontal disease  
Periodontal diseases are infections of the structures around the teeth, which include 
the gums, periodontal ligament and alveolar bone. In the earliest stage of periodontal 
disease (gingivitis) the infection affects the gums. In more severe forms of the 
disease, all of the tissues are involved. The classifications and corresponding 
conditions of periodontal disease are presented in Table 2.1 (Armitage, 1999). 
 
2.2  Pathophysiology of periodontal disease    
Figure 2.1 shows the anatomy of the periodontium. The normal periodontal tissue is 
comprised of gingival, periodontal ligament, cementum and alveolar bone. 
Histologically, gingival mucosa is a stratified squamous epithelium with underlying 
connective tissue, which is rich in blood vessels and nerves. The main function of 
the periodontium is to support the teeth to the jaw bone. It is specifically structured 
against mechanical and microbial damage, which acts as a barrier to penetration by 
microbial and noxious agents into deeper tissues (Cawson & Odell, 2008). 












Classification Conditions  
Gingival Disease 
       (GD) 
A. Dental plaque 
induced GD 
1. Gingivitis associated with plaque only. 
2. GD modified by systemic factors. 
3. GD modified by medications. 
4. GD modified by malnutrition. 
B. Non plaque 
induced gingival 
lesions 
1. GD of specific bacterial/viral/fungal 
origin. 
2. Gingival lesions of genetic origin 
3. Gingival manifestations of systemic 
diseases. 
4. Traumatic lesions. 
5. Foreign body reaction. 









Periodontitis as a 
Manifestation of 
Systemic Disease 
A. Associated with 
haematological 
disorder 
1. Acquired neutropenia. 
2.‎Leukaemia’s. 
3. Others. 
B. Associated with 
genetic disorders 
1. 12 genetic classifications. 




A. Necrotising ulcerative gingivitis. 
B. Necrotizing ulcerative periodontics. 
Abscesses of  
Periodontium 
A. Gingival abscess 
B. Periodontal abscess 









A. Localized tooth related factors. 
B. Mucogingival deformities and conditions around tooth. 
C. Mucogingival deformities and conditions on edentulous 
ridge. 
D. Occlusal trauma 
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The gingival mucosa has high permeability characteristic, which leads to its 
popularity as a route of administration for both local and systemic drug delivery 
(Montero-Padilla  et al., 2016). The oral cavity is host to both aerobic and anaerobic 
bacteria forming a symbiotic relationship (Pihlstrom et al., 2005). Poor oral hygiene 
can cause inflammation when a layer of bacteria and food debris, known as plaque, 
builds up and is left undisturbed at the gingival margin. This leads to abundant 
plaque and calculus beneath the gingival margin, which start to cause the 
inflammation. This inflammation is called gingivitis which appears to be red, 
swollen and can bleed easily. The inflammatory process is to defend the host. 
However, the process may also lead to tissue destruction. If the gingivitis is left 
untreated, it may progress and cause inflammation to the periodontium eventually 
known as periodontitis (Figure 2.2). The presence of bacteria in plaque, can release 
toxins that lead to a cascade of inflammatory events. The inflammatory mediators 
include cytokines, prostaglandins, and enzymes from neutrophils and monocytes. 
The resulting inflammation affects the periodontal ligament, causing breakdown of 
tissues and bones supporting the teeth. This leads to formation of a space which acts 
as a reservoir for growth and multiplication of microorganisms. 
 
Pocket depth is a clinical indication of the severity of periodontitis, which results in 
tooth mobility and subsequent loss of the tooth in later stages. As the disease 
progresses, more bacterial multiplication takes place in the periodontal tissue. As a 
result of inflammation, a fluid known as gingival crevicular fluid (GCF) exudates 





Figure 2.2.  Pathogenesis mechanism resulting in periodontal disease (adapted from 
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Briefly, the stages of periodontal disease begin with development of gingivitis, 
followed by periodontal pockets and subsequent progression causing periodontitis 
(Figure 2.3).  
 
Figure 2.3. Stages of periodontal disease (adapted from Michael, 2017). 
 
 
Generally, in periodontal disease, two features appear namely, the presence of the 
causative agent of the infection which is the microorganism and inflammatory 
mediator as a response to the inflammation process which leads to tissue destruction 
(Cekici et al., 2014). 
 
2.3  Periodontitis    
Periodontitis is a set of inflammatory diseases  that damage the soft tissue 
periodontium  surrounding the teeth. It is an irreversible inflammatory condition, 
which involves progressive loss of the alveolar bone around the teeth and can lead to 
tooth loss (Graetz et al., 2017). Periodontitis is preventable. Treatment can reduce 
the rate of tooth loss and improve the quality of life. The interaction between 
bacteria and the immune-inflammatory response may lead to periodontal tissue 
destruction (Vardar et al., 2003). 
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2.4  Causative agents for periodontal disease    
The oral cavity provides a diversed environment for colonization by a wide variety of 
microorganisms. Microbial colonization on the teeth is a major source of pathogens 
responsible for oral and dental infections, including periodontal disease, gingivitis, 
post extraction infections and endodontitis. It is estimated that about 200 - 500 
microorganisms are present in the periodontal pocket (Southard and Godowski, 
1998) with a predominant number of Gram-negative and anaerobic bacteria 
(Mikkelsen et al., 2008).  
 
The microorganisms gather in the periodontal pocket and develop as a biofilm 
between the affected teeth and tissue. As the disease progresses, so does the depth of 
the periodontal pocket. The release of bacterial leukotoxins, collagenases, 
fibrinolysins and other proteases, causes tissue destruction and facilitates bacterial 
invasion (Pihlstrom et al., 2005). The use of antimicrobial agents in periodontal 
therapy is due to the microbial etiology of periodontal disease (Research, Science 
and Therapeutic Committee of the American Academy of Periodontology, 2004). 
 
2.5  Inflammatory process in periodontal disease    
Following local tissue destruction by bacterial infection to the periodontium, 
arachidonic acid is released and metabolized by cyclooxygenase enzyme (COX), 
which is present in two forms, COX-1, antithrombogenic and cytoprotective, and 
COX-2, inducing the production of prostaglandins (Vardar et al., 2003). 
Prostaglandins have potent inflammatory properties and prostaglandin E2, which is 
readily detectable in acute inflammatory exudates, is formed as inflammatory 
mediators. In periodontal disease, the concentration of prostaglandin is increased in 
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the gingival tissue (Pouliot et al., 2000). Therefore, a potential mechanism for 
blocking periodontal progression may depend on use of non-steroidal anti-
inflammatory drugs by inhibiting prostaglandin synthesis (Salvi and Lang, 2005). 
The administration of nonsteroidal anti-inflammatory drugs decreases inflammation 
and relieves pain (Figure 2.4).  
 
Figure 2.4.  Inflammation steps and how NSAIDs block the inflammation (adapted 
from creatingtechnology.org. Index of / biomed/aspirin_ files.  
2.6 Therapeutic agents in treatment of periodontal diseases    
The success of periodontal disease treatment is largely dependent on the mode of 
administration and the type of therapeutic agent administered (Addy & Fugit, 1989; 
Goodson, 1994).  
 
Several therapeutic approaches have been developed and studied to enhance the 
clinical improvement of scaling and root planning (SRP). Oral administration of 
antibiotics, metronidazole and amoxicillin significantly improved the clinical 
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appearance of patients with aggressive periodontitis (Guerrero et al., 2005). Haffajee 
et al. (2007) conducted a study over 12 months, assigning patients to receive SRP 
alone or in combination with metronidazole, azithromycin or doxycycline. All the 
groups demonstrated that adjunct antibiotics provided a clinical benefit over SRP 
alone. Table 2.2 summarizes the commonly used antibiotics in the treatment of 
periodontal disease. 
 
Nevertheless, oral administration of antibiotics demonstrates several problems, 
which include gastrointestinal intolerance, hypersensitivity and development of 
bacterial resistance (Bollen & Quirynen, 1996; Mombelli et al., 1997; Dodwad et al., 
2012). Moreover, a high antibiotic dose is required to achieve the therapeutic 
concentration at the targeted site of action, which in turn causes side effects in 
patients (Ardila et al., 2010a). This drawback can be overcome if the antimicrobial 
agent is applied locally. A number of local delivery devices have been developed in 
site - specific therapies to minimize systemic effect exposure and risk in patients 
(Schwach et al.,  2000). 
 
The therapeutic success or failure of antimicrobial agents depends not only on 
antimicrobial activity but also the location, carrier system and route of 
administration. Local administration of therapeutic agents targets the causative agent 






Table 2.2. Antimicrobial agents used in the treatment of periodontal disease. 
Antibiotics Mechanism of 
action 




























(Walker et al., 
1981; 
Van et al., 
2005) 
Clarithromycin        
/ 
Azithromycin    
Binds to 23S 
rRNA, a 
component of the 


















synthesis in cell 
wall of bacteria. 
Mycobacterium micros 
Porphyromonas 
gingivalis and  
Actinobacillus 
actinomycetemcomitans 
(Winkel  et al.,  
2001; 















(Tözüm et al.,  
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2.7  Advantages and limitations of local drug delivery in treatment ofperiodontal 
disease   
 Local drug delivery systems have several advantages: 
 Formulation is light and easily placed into the periodontal cavity without pain. 
 Capable of delivering therapeutic concentrations of drug for prolonged period with 
lower dose, hence obviating untoward side effects.  
 Decrease in dosing frequency. 
 By-pass hepatic first pass  metabolism.  
 Localized drug action and enhanced therapeutic efficacy of the drug by maintaining 
high levels (can be 100 folds higher compared to systemic) of antibiotic in the 
gingival crevicular fluid (GCF) which prevents infections caused by antibiotic-
resistant bacteria. 
 More cost-effective treatment to patients. 
 High patient compliance and better clinical outcome compared to systemic 
administration. 
 Safe and more convenient route of drug administration. 
 Antibiotics with short half-lives can be used more efficiently.  
The limitation of using local delivery system for periodontitis is that the dose 
content  is limited because of a relatively small area of site of application (Nair & 
Anoop, 2012). Also, the presence of enzymes like esterase and peptidase may cause 





2.8  Characteristics of local drug delivery systems   
The local drug delivery systems should have the following characteristics (Puri & 
Puri, 2013) :  
 Medication must reach planned site of action. 
 Stay at adequate concentration. 
 Last for an adequate duration. 
 Easy application 
 
2.9  Local delivery devices for treatment of periodontal disease     
Different local delivery devices for in situ treatment of periodontal disease have 
been developed. Numerous chemotherapeutic agents particularly antimicrobial and 
anti-inflammatory drugs have been loaded into a polymeric matrix, where the matrix 
plays a role in drug release. For periodontitis, different drug delivery systems have 
been evaluated and they can be broadly classified into fibers, films, gels, rods, 
buccoadhesive tablets, discs, chips, spheres, nanoparticles and vesicles (Plate 2.1). 
 
2.9.1   Fibers 
Goodson (1985) was the first who developed and tested fibers with antimicrobial 
agents. The fiber needed to be placed into pockets with applicators and secured with 
cyanoacrylate adhesive. A number of polymers have been used for the delivery of 
antimicrobial agents such as cellulose acetate propionate, polyurethane, 
polypropylene and ethyl vinyl acetate (EVA). Development in fiber technology has 
led to the FDA approval of non-degradable biological inert plastic polymer ethylene 
and vinyl-acetate loaded with 12.3 mg of tetracycline hydrochloride over a period of 
10 days (Goodson et al.,1985). The disadvantage of Actisite
®
 was the difficulty in 
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placement and removal from the site of application. Biodegradable form of fiber 
known as Periodontal Plus AB, a collagen fibril based formulation having a dual 
mode of actions was  also developed (Garg, 2015).  
 
 
2.9.2   Film  
Films are matrix delivery devices in which the drug is distributed throughout the 
polymer. Drug release occurs by diffusion and /or matrix dissolution. It is used 
widely in the development of local delivery for treatment of periodontal disease. A 
number of biodegradable and bioadhesive polymers have been used for the delivery 
of antimicrobial agents such as polyesters, hydroxyl propyl cellulose, and cross-
linked collagen and protein film (Garg, 2015). Films are not required to be removed 
after treatment and they do not need adhesive agent to remain at the site of 
treatment. Newer distinguishable films composed of poly (vinyl alcohol) (PVA) and 
carboxyl methyl- chitosan (CMCS) were prepared by blending / casting methods 
and were found to be biocompatible (Vyas et al.,2000). 
The main drawback of this device is the difficulty in securing the film in place with 
normal flushing of the periodontal pocket (Jones et al., 1996). Moreover, this device 
is not evenly located inside the periodontal pocket compared to other devices. This 




























    
  
19 
2.9.3   Gels 
Gels have a semi-solid consistency and can be applied with the help of a blunt 
cannula and syringe. Gels have the advantages of being easily administered and 
being evenly distributed throughout the periodontal pocket. Moreover, gels show 
high biocompatibility, biodegradation and bioadhesion  to the mucosa, which help to 
decrease the risk of irritation and allergic reaction at the site of application. The 
presence of bioadhesive polymer helps the gel to remain at the periodontal pocket. 
Atridox
®
 is an FDA approved gel loaded with 8.5% doxycycline (Karpinia & 
Magnusson, 2000). It is available in 2 syringes and solidifies within the 
periodontium. The level of doxycycline was above the minimum inhibitory 
concentration and could be maintained for 10 days (Kim et al.,  2004). In addition, 
about 95% of the polymers were bioabsorbed or expelled from the pocket within 28 
days (Garg, 2015). 
 
2.9.4   Nanoparticles  
Nanoparticles may be spheres, tubes, capsules, fibers or rods with particle size of 
0.01-0.1 μm. Owing to their small size, it can reach deep into the periodontal pocket 
that may be inaccessible to other delivery devices. These systems reduce the 
frequency of administration and provide uniform distribution of the active agent 
over a long period. Various studies have been carried out to evaluate the efficacy of 
nanoparticles in the treatment of periodontal diseases. Combination of SRP and 
metronidazole nanofibers provided added benefits compared to the control group 
(Chaturvedi et al.,  2012). Ferreira et al. (2017) showed reduction in the P. gingivalis 
growth in the dental GCF after being implanted with nano-tube entrapped with 
doxycycline over a 28-day treatment. 
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2.9.5   Microparticles 
Microparticles include microspheres and microcapsules with particle size ranging 
from 1‎to‎1000‎μm. Both biodegradable and non-biodegradable polymeric materials 
have been investigated for the preparation of microparticles. Microparticle based 
system of biodegradable poly alpha hydroxyl acids containing tetracycline have 
been formulated for periodontal therapy. An improvement in tetracycline delivery to 
the periodontal pocket was achieved by increasing the drug release quantity and 
period of sustained release  (Liu et al., 2004). Poly (lacto-co-glycolic acid) 
microspheres loaded with minocycline have been prepared to eradicate P. gingivalis 
from the periodontal pocket and reduce the plaque as well as gingival inflammation 
(Jhinger et al., 2015). A controlled release device consisting of two layers of 
sandwich membrane containing collagen sponge scaffold and gelatin microspheres 
loaded with basic fibroblast growth factor acting as an anti-inflammatory agent to 
regenerate periodontal tissue was reported (Garg, 2015). 
 
2.9.6   Vesicular systems  
Liposomal systems mimic the bio-membrane in terms of behavior and structure, and 
hence are used intensively for targeting the periodontal biofilm. The targeting by 
liposome was due to interaction between the lipid incorporating vesicles and the 
surface of the bacteria by adsorption process. The delivery of metronidazole bearing 
liposome  showed a potential system for targeting bacterial biofilm which controlled 
dental plaque and gingivitis (Vyas et al., 2001). Succinylated concanavalin A 
(lectin)-bearing liposome has been applied for the delivery of antibacterial triclosan 
which is sparingly soluble in water. The proteoliposomes and the 
dipalmitoylphosphatidylcholine (DPPC) and phosphatidylinositol (PI) liposomes 
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containing low levels of triclosan inhibited bacterial growth more effectively than 
equivalent levels of free bactericide (Jones et al., 1994). 
 
2.9.7   Local drug delivery devices published or available commercially  
Table 2.3 summarizes the publications of various local drug delivery systems 
containing antimicrobial agents in the treatment of used in periodontal disease.  




Type of study References 
Amoxicillin Fiber In vitro (Ahuja et al., 2006a) 
Amoxicillin Denticap In vitro (Mukherjee et al., 2009) 
Chlorhexidine 
Film In vitro 
(Friedman & Golomb, 
1982) 
Chlorhexidine Strip In vivo (humans) 
(Addy & Langeroudi, 
1984) 
Chlorhexidine Strip In vivo (humans) 
(Kamura & Suzuki, 1984) 
 
Chlorhexidine Strip In vivo (humans) (Addy et al., 1988) 
Chlorhexidine Film In vitro (Steinberg et al.,1990) 
Chlorhexidine 
Film In vitro                          
(Cetin et al., 2004) 
 
Chlorhexidine Chip In vitro 
(Yue et al., 2004) 
 
Chlorhexidine Film In vitro  
(Tallury et al., 2007) 
 
Chlorhexidine Film In vitro 
(Arnold et al., 2008) 
 
Chlorhexidine Chip In vivo (humans) 
(Jothi et al., 2009) 
 
Chlorhexidine 
Film In vitro 
(Huynh et al., 2010) 
Chlorhexidine 
Gel In vitro    (Bako et al., 2008) 
Chlorhexidine Chip In vivo (humans) 
(Machtei et al., 2011) 
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Chlorhexidine Sphere In vitro 
(Luo et al.,  2016) 
 
Clindamycin Film In vivo (animals) 
(Higashi et al., 1991) 
 
Ciprofloxacin Film In vitro 
(Ahmed et al., 2009) 
 
Doxycycline Strip In vivo (humans) 
(Taner et al., 1994) 
 
Doxycycline Micro particle In vivo (humans) (Mundargi et al., 2007) 
Doxycycline 
Gel In vitro 
(Obaidat et al., 2010) 
 
Doxycycline Film In vivo (humans) 
(Mahmoud et al., 2016) 
 
Gentamycin Fiber In vitro 
(Chang et al., 2008) 
 
Levofloxacin Gel In vitro 
(Sapra  et al., 2013) 
 
Metronidazole Strip In vivo (humans) 
(Addy & Langeroudi, 
1984) 
Metronidazole Film In vivo (humans) 
(Golomb et al., 1984) 
 
Metronidazole Gel In vitro 
(Jones et al., 1997a) 
 
Minocycline Film In vivo (humans)  
(Elkayam et al., 1988)   
 
Minocycline Film In vitro 
(Kyun et al., 1990) 
 
Minocycline Ointment In vivo (humans) 
(Nakagawa et al.,1991) 
 
Minocycline Microsphere In vivo (humans) 
(Williams et al., 2001) 
 
Minocycline Gel In vivo 
(Soeroso  et al., 2017) 
 
Ofloxacin Strip In vivo (humans) 
(Higashi et al., 1990) 
 
Tetracycline Fiber In vivo (humans) (Goodson et al., 1979) 
Tetracycline Strip In vivo (humans) (Noguchi et al., 1984) 
Tetracycline Strip In vivo (humans) (Addy  et al., 1988) 
Tetracycline Film In vitro (Azoury et al., 1988) 
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Tetracycline) Film In vivo (humans) (Minabe et al., 1989) 
Tetracycline Compact In vivo (humans) (Collins et al., 1989) 
Tetracycline Film In vivo (humans) (Agarwal et al., 1993) 
Tetracycline Semi-solid In vivo (humans) (Roskos et al., 1995) 
Tetracycline Strip In vivo (humans) (Maze et al., 1995) 
Tetracycline Gel In vitro (Jones et al.,1996) 
Tetracycline Micro particle In vitro (Esposito et al., 1997) 
Tetracycline Mesh In vitro (Park et al., 1997) 
Tetracycline Microsphere In vitro (Govender et al.,2005) 
Tetracycline Film In vitro (Owen et al., 2010) 
Ornidazole Film In vitro (Shankraiah et al., 2011) 
Sparfloxacin Strip In vitro (Muchalambe et al. 2010) 











Some of the commercially available local delivery devices containing antimicrobial 
agents are summarized in Table 2.4.   






Actistite® Tetracycline HCL 
25% 
Fiber Alza and Procter & Gamble   
Arestin® Minocycline 
2% 
Microsphere OroPharma Inc., 
Warminster,  PA 
Atridox® Doxycycline 
10% 





Gel Sunstar corp., Tokyo, 
Japan; 
Wayne, NJ, USA 
Periocline® Minocycline 
2.1% 
Gel Sunstar Americas 
Elyzol® Metronidazole 
25% 
Gel Dumex corp. Co Denmark 
Periocol ™ Chlorhexidine 
1% 














Gel Ghimas Company, Italy 
Corsodyl® Chlorhexidine 
1% 







Table 2.5 shows the publications of local delivery devices containing two or more 
antibiotics. 
 
 
